A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1

PHASE3CompletedINTERVENTIONAL
Enrollment

1,057

Participants

Timeline

Start Date

December 10, 2015

Primary Completion Date

June 1, 2021

Study Completion Date

November 11, 2021

Conditions
Multiple Sclerosis
Interventions
DRUG

ALKS 8700

Administered as specified in the treatment arm.

Trial Locations (115)

1309

Alkermes Investigational Site, Sofia

1606

Alkermes Investigational Site, Sofia

1797

Alkermes Investigational Site, Sofia

2700

Alkermes Investigational Site, Blagoevgrad

4103

Alkermes Investigational Site, Leipzig

4557

Alkermes Investigational Site, Fraiture

5800

Alkermes Investigational Site, Pleven

7100

Alkermes Investigational Site, La Louvière

8000

Alkermes Investigational Site, Bruges

10713

Alkermes Investigational Site, Berlin

11000

Alkermes Investigational Site, Belgrade

11772

Alkermes Investigational Site, Patchogue

11794

Alkermes Investigational Site, Stony Brook

11803

Alkermes Investigational Site, Plainview

12099

Alkermes Investigational Site, Berlin

13210

Alkermes Investigational Site, Syracuse

18000

Alkermes Investigational Site, Niš

19107

Alkermes Investigational Site, Philadelphia

20007

Alkermes Investigational Site, Washington D.C.

23228

Alkermes Investigational Site, Richmond

23601

Alkermes Investigational Site, Newport News

26655

Alkermes Investigational Site, Westerstede

27103

Alkermes Investigational Site, Winston-Salem

27405

Alkermes Investigational Site, Greensboro

27607

Alkermes Investigational Site, Raleigh

28203

Alkermes Investigational Site, Charlotte

28905

Alkermes Investigational Site, Madrid

29307

Alkermes Investigational Site, Spartanburg

29406

Alkermes Investigational Site, Charleston

29650

Alkermes Investigational Site, Greer

29732

Alkermes Investigational Site, Rock Hill

30327

Alkermes Investigational Site, Atlanta

30342

Alkermes Investigational Site, Atlanta

31904

Alkermes Investigational Site, Columbus

32174

Alkermes Investigational Site, Ormond Beach

32209

Alkermes Investigational Site, Jacksonville

32751

Alkermes Investigational Site, Maitland

32960

Alkermes Investigational Site, Vero Beach

33462

Alkermes Investigational Site, Atlantis

33634

Alkermes Investigational Site, Tampa

34000

Alkermes Investigational Site, Kragujevac

34102

Alkermes Investigational Site, Naples

34209

Alkermes Investigational Site, Bradenton

34239

Alkermes Investigational Site, Sarasota

35058

Alkermes Investigational Site, Cullman

37064

Alkermes Investigational Site, Franklin

37922

Alkermes Investigational Site, Knoxville

38010

Alkermes Investigational Site, Santa Cruz de Tenerife

38018

Alkermes Investigational Site, Cordova

40513

Alkermes Investigational Site, Lexington

43210

Alkermes Investigational Site, Columbus

44718

Alkermes Investigational Site, Canton

45417

Alkermes Investigational Site, Dayton

46202

Alkermes Investigational Site, Indianapolis

46260

Alkermes Investigational Site, Indianapolis

48202

Alkermes Investigational Site, Detroit

49005

Alkermes Investigational Site, Dnipro

49684

Alkermes Investigational Site, Traverse City

50314

Alkermes Investigational Site, Des Moines

55422

Alkermes Investigational Site, Golden Valley

60201

Alkermes Investigational Site, Evanston

61068

Alkermes Investigational Site, Kharkiv

61103

Alkermes Investigational Site, Kharkiv

63104

Alkermes Investigational Site, St Louis

63110

Alkermes Investigational Site, St Louis

63131

Alkermes Investigational Site, St Louis

65025

Alkermes Investigational Site, Odesa

66037

Alkermes Investigational Site, Krasnoyarsk

66213

Alkermes Investigational Site, Overland Park

69035

Alkermes Investigational Site, Zaporizhzhya

69600

Alkermes Investigational Site, Zaporizhzhya

70810

Alkermes Investigational Site, Baton Rouge

71301

Alkermes Investigational Site, Alexandria

73104

Alkermes Investigational Site, Oklahoma City

75231

Alkermes Investigational Site, Dallas

76008

Alkermes Investigational Site, Ivano-Frankivsk

77030

Alkermes Investigational Site, Houston

77074

Alkermes Investigational Site, Houston

79000

Alkermes Investigational Site, Lviv

79410

Alkermes Investigational Site, Lubbock

80111

Alkermes Investigational Site, Centennial

80209

Alkermes Investigational Site, Denver

81621

Alkermes Investigational Site, Basalt

84103

Alkermes Investigational Site, Salt Lake City

85004

Alkermes Investigational Site, Phoenix

85018

Alkermes Investigational Site, Phoenix

85032

Alkermes Investigational Site, Phoenix

85704

Alkermes Investigational Site, Tucson

87106

Alkermes Investigational Site, Albuquerque

89073

Alkermes Investigational Site, Ulm

89081

Alkermes Investigational Site, Ulm

90806

Alkermes Investigational Site, Long Beach

92103

Alkermes Investigational Site, San Diego

92354

Alkermes Investigational Site, Loma Linda

94705

Alkermes Investigational Site, Berkeley

97504

Alkermes Investigational Site, Medford

98101

Alkermes Investigational Site, Seattle

98122

Alkermes Investigational Site, Seattle

98133

Alkermes Investigational Site, Seattle

603155

Alkermes Investigational Site, Nizhny Novgorod

06762

Alkermes Investigational Site, Middlebury

06905

Alkermes Investigational Site, Stamford

30312-4201

Alkermes Investigational Site, Atlanta

J8Y 1W2

Alkermes Investigational Site, Gatineau

01307

Alkermes Investigational Site, Dresden

80-803

Alkermes Investigational Site, Gdansk

40-123

Alkermes Investigational Site, Katowice

40-648

Alkermes Investigational Site, Katowice

25-726

Alkermes Investigational Site, Kielce

31-505

Alkermes Investigational Site, Krakow

90-324

Alkermes Investigational Site, Lodz

20-718

Alkermes Investigational Site, Lublin

62-064

Alkermes Investigational Site, Plewiska

70-111

Alkermes Investigational Site, Szczecin

08916

Alkermes Investigational Site, Barcelona

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Alkermes, Inc.

INDUSTRY

lead

Biogen

INDUSTRY

NCT02634307 - A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1 | Biotech Hunter | Biotech Hunter